Aarti Drugs Limited

Equities

AARTIDRUGS

INE767A01016

Pharmaceuticals

Delayed Bombay S.E. 03:57:20 2024-04-18 am EDT 5-day change 1st Jan Change
496.7 INR +0.40% Intraday chart for Aarti Drugs Limited -1.52% +1.56%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Aarti Drugs Limited Announces Executive Cessation CI
Aarti Drugs Begins Manufacturing Dermatology Products in Tarapur, India Facility MT
Aarti Drugs Limited Initiates Commercial Production of Dermatology Product At New Facility in Tarapur, Maharashtra CI
Transcript : Aarti Drugs Limited, Q3 2024 Earnings Call, Jan 25, 2024
Aarti Drugs Limited Announces Interim Dividend for the Financial Year 2023- 24 CI
Aarti Drugs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Transcript : Aarti Drugs Limited, Q2 2024 Earnings Call, Oct 20, 2023
Aarti Drugs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Tranche Update on Aarti Drugs Limited's Equity Buyback Plan announced on July 21, 2023. CI
Aarti Drugs Limited's Equity Buyback announced on July 21, 2023, has closed with 665,000 shares, representing 0.72% for INR 598.5 million. CI
Aarti Drugs Clocks Gains in Fiscal Q1 Consolidated Profit MT
Transcript : Aarti Drugs Limited, Q1 2024 Earnings Call, Jul 24, 2023
Aarti Drugs Limited announces an Equity Buyback for 665,000 shares, representing 0.72% for INR 598.5 million. CI
Aarti Drugs Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Aarti Drugs Limited authorizes a Buyback Plan. CI
Aarti Drugs Limited's Board intends to launch an Equity Buyback on July 21, 2023. CI
Aarti Drugs Limited's Board intends to launch an Equity Buyback on July 21, 2023. CI
Transcript : Aarti Drugs Limited, Q4 2023 Earnings Call, May 02, 2023
Aarti Drugs' Consolidated Profit Climbs in Fiscal Q4 MT
Aarti Drugs Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
Transcript : Aarti Drugs Limited, Q3 2023 Earnings Call, Jan 30, 2023
Aarti Drugs' Consolidated Net Profit Declines in Fiscal Q3 MT
Aarti Drugs Limited Declares Interim Dividend for the Financial Year 2022-23 CI
Aarti Drugs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Aarti Drugs' Consolidated Profit Falls in Fiscal Q2 MT
Chart Aarti Drugs Limited
More charts
Aarti Drugs Limited is an India-based company that is engaged in the manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates, specialty chemicals and formulations. The Company operates through pharmaceuticals segment. The Company's APIs products include ciprofloxacin hydrochloride, metronidazole, metformin HCL, ketoconazole and ofloxacin, among others. Its specialty chemicals products include benzene sulphonyl chloride and methyl nicotinate, among others. Its pharma intermediates products include tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, raloxifene and zolpidem. Its products under development include itraconazole, fluconazole, dabigatran, ticagrelor, sitagliptin and alpha lipoic acid. The Company's subsidiaries include Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SPA.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
494.7 INR
Average target price
562 INR
Spread / Average Target
+13.60%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. AARTIDRUGS Stock
  4. News Aarti Drugs Limited
  5. Aarti Drugs : Board Approves Buyback of Shares Worth Over $8 Million